(VIANEWS) – The NASDAQ opens in less than two hours and Xenetic Biosciences‘s pre-market value is already 11.62% up.
Xenetic Biosciences’s last close was $0.42, 62.83% under its 52-week high of $1.13.
The last session, NASDAQ ended with Xenetic Biosciences (XBIO) falling 0.02% to $0.42. NASDAQ rose 0.69% to $12,226.58, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xenetic Biosciences’s EBITDA is 6.09.
Sales Growth
Xenetic Biosciences’s sales growth is 5.4% for the present quarter and 5.5% for the next.
Volume
Today’s last reported volume for Xenetic Biosciences is 27438 which is 38.61% below its average volume of 44203.
More news about Xenetic Biosciences (XBIO).
